Navigation Links
BioXpress Therapeutics SA to Partner the 2011 BIO International Convention
Date:6/15/2011

monoclonal antibody. To ensure BioXpress Therapeutics has identified the correct sequence, the Company has developed a proprietary database of protein sequences based on comprehensive analysis of literature and patent databases. All data entry and data analysis is done by the Company's team which consists of scientists who have been actively involved in making monoclonal antibody therapeutics since the early 1980s. As a result, the BioXpress scientific team is well-versed in the literature and groups who have developed many of the originator MAbs over the decades. Based on the data from the BioXpress database, the biosimilar protein is expressed and compared to the originator to ensure a valid sequence before moving the drug forward.

About BioXpress Therapeutics

BioXpress Therapeutics SA is a privately held biotechnology committed to developing and supplying the highest quality and cost-competitive biosimilar biologic API for unmet need indications such as cancer, inflammation and autoimmunity.  Headquartered in Geneva, Switzerland, BioXpress Therapeutics business is focused on developing unbranded monoclonal antibody (MAb and MAb-like) biosimilar drugs under strict European Medicines Agency (EMA) guidelines.

For more information visit www.bioxpress.com.

Media Contact

Robert Meister
602-953-1716
robert@meister.net


'/>"/>
SOURCE BioXpress Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings
2. Cell Therapeutics on Preliminary List of Additions to Russell 3000® Index and Russell Global Index
3. Northwest Biotherapeutics Announces Change and Expansion of Management Team
4. Northwest Biotherapeutics Announces Series of Financing Arrangements
5. Healthpoint Biotherapeutics Acquires Regranex® Gel
6. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
7. Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
9. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
10. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
11. Nile Therapeutics to Transition to OTCQB Marketplace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 The laboratory information ... has witnessed a number of technological advancements due to ... requirements, growing need to integrate healthcare systems, and increasing ... challenges in system integration. Key players in the market ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Approval of Genasense in Relapsed/Refractory Patients, BERKELEY ... GNTA ) announced that the Company has completed ... Janet Woodcock, Acting,Director of the Center for Drug ... Administration (FDA). The appeal asks that CDER approve ...
... Cell,Genesys, Inc. (Nasdaq: CEGE ), today announced ... and Sharon E. Tetlow, senior,vice president and chief financial ... to the company,s third quarter financial results,that will be ... at 2:00 p.m. PT/ 5:00 p.m. ET. The ...
... Include World-Renowned RNase and RNA Researchers, SOMERSET, ... of ribonuclease (RNase) therapeutics will be the focus ... by Alfacell,Corporation (Nasdaq: ACEL ). Moderated ... officer, and David Sidransky, M.D., Alfacell,s scientific,advisory board ...
Cached Biology Technology:Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5Cell Genesys to Webcast Third Quarter 2007 Conference Call 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 3Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 4
(Date:1/22/2015)... YORK , Jan. 22, 2015   EyeLock, Inc. , ... it has appointed Steve Gerber to the new ... will be responsible for leading development of mobile platforms and ... years of success and innovation in the semiconductor industry to ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today announced the ... ancestry of individuals from across the United States ... four hundred years ago, the United States ... different continents. This study illuminates how American history and the ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... UT Southwestern neuroscience researchers have identified a gene that controls ... mice often used to study addiction and behavior patterns. ... , determines how mammals respond to cocaine, although it is ... or for addiction, said Dr. Joseph Takahashi , chair ...
... Department of Energy,s Brookhaven National Laboratory have identified a ... class of plant products with a wide range of ... source of flavors, fragrances, and pigments; some are of ... contribution to the construction of plant cell walls, (poly)phenols ...
... of superstars in the materials world. Already prized for ... identity, vanadium dioxide can now add muscle power to ... Department of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... from vanadium dioxide that for its size is a ...
Cached Biology News:UT Southwestern neuroscience researchers identify gene involved in response to cocaine 2Enlisting cells' protein recycling machinery to regulate plant products 2A micro-muscular breakthrough 2A micro-muscular breakthrough 3